MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

6.8 0.74

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.75

Max

6.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

30M

-36M

Pardavimai

1.6M

31M

Pelnas, tenkantis vienai akcijai

-0.35

Pelno marža

-117.018

Darbuotojai

181

EBITDA

24M

-40M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+313.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-145M

659M

Ankstesnė atidarymo kaina

6.06

Ankstesnė uždarymo kaina

6.8

Naujienos nuotaikos

By Acuity

50%

50%

115 / 375 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-05 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 15:57; UTC

Rinkos pokalbiai

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025-07-04 15:49; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Received All Required Authorizations

2025-07-04 15:48; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Agreement Was Announced on Dec. 19

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025-07-04 15:46; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025-07-04 14:30; UTC

Įsigijimai, susijungimai, perėmimai

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025-07-04 13:53; UTC

Rinkos pokalbiai

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-04 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus -2-

2025-07-04 12:30; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

2025-07-04 12:15; UTC

Rinkos pokalbiai

Targeted Tariffs Would Likely Support Dollar -- Market Talk

2025-07-04 12:13; UTC

Rinkos pokalbiai

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

2025-07-04 12:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

313.82% į viršų

12 mėnesių prognozė

Vidutinis 28.14 USD  313.82%

Aukščiausias 36 USD

Žemiausias 20 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

7

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

115 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.